Tag Archives: ARB

Introduction Device therapy has revolutionised the landscape of heart failure over the past 10 years. Prior to device therapy, the most important trials in heart failure (HF) management centred on pharmacotherapy. The CONSENSUS (Cooperative North Scandinavian Enalapril Survival Study) trial (1987),1 showed the importance of optimal blockade of the renin–angiotensin–aldosterone system (RAAS). Similarly, CIBIS-II (Cardiac Insufficiency Bisoprolol Study II) (1999)2 and RALES (Randomized Aldactone Evaluation Study) (1999)3 trials did the same for beta-blockade and spironolactone, respectively. This century, device therapy has also become part

Presenters included cardiologists, Professors Michael Boehm (University of the Saarland, Homburg, Saarland, Germany) and Stefan Anker (University Medical Center Göttingen, Göttingen, Germany) and nephrologist, Matthew Weir (University of Maryland Medical Centre, Baltimore, Maryland, USA). Their presentations are summarised below. The addition of mineralocorticoid receptor antagonists (MRAs) to angiotensin converting enzyme (ACE) inhibition or receptor blockade (ARB) has been shown in randomised-controlled trials to improve morbidity and mortality in patients with heart failure.1,2 In the EMPHASIS-HF study, the addition of eplerenone in pat

Studies involving nearly 6,000 patients with hypertension have shown it lowers blood pressure (BP) significantly more than ramipril, valsartan and olmesartan medoxomil when compared at their maximum doses. It also maintains BP lowering over a 24-hour period. Data on the new compound were presented by Professor Luis Ruilope, (Hospital 12 de Octubre, Madrid, Spain) at a Takedasponsored symposium during the 22nd European Society of Hypertension (ESH) meeting, held in London from 26th–28th April recently. In one study with ramipril, azilsartan 80 mg once daily provided a 9/6 mmHg greater reduction in clinic BP than ramipril 10 mg once daily, at

No content available